In this paper, we give an overview of the research progress in CRISPR therapeutics by analyzing data from the CAS Content Collection TM . The CAS Content Collection is the largest human-curated collection of published scientific information, supporting comprehensive quantitative analysis of global research across parameters including time, geography, scientific discipline, application, disease, chemical composition, etc. Covering scientific literature published around the world in more than 50 languages, the CAS Content Collection encompasses data and discoveries published in more than 50,000 scientific journals and by over 100 patent offices. A major advantage provided by the CAS Content Collection is that, along with the standard reference information, it also provides human curated data on major substances and concepts explored in scientific publications. The CAS REGISTRY, the authoritative source for information on more than 250 million unique organic and inorganic substances and 70 million protein and nucleic acid sequences, is part of the CAS Content Collection. The CAS Content Collection is broadly accessible through CAS solutions including CAS SciFinder® 34 and CAS STNext®. Here we examine the publication landscape in the area in an effort to provide insights into current knowledge, advances and developments. We review the most discussed and emerging concepts and assess therapeutic strategies. Relying on the expertise and knowledge of our subject matter experts, we have analyzed the corpus of CRISPR-related publications to determine/highlight interesting trends in terms of protein targets often targeted using CRISPR, the co-occurrences between diseases and protein targets, prevalence of different CRISPR/Cas proteins, leading commercial and non-commercial entities engaged in research related to CRISPR. Finally, we inspect clinical applications of CRISPR therapeutics and diagnostics with details of their development. The objective of this review is to provide a broad overview of the evolving landscape of current knowledge regarding CRISPR application in therapeutics and diagnostics, to outline challenges that lie ahead, and evaluate growth opportunities to further efforts in this groundbreaking technology.